Brigitte Trétarre1, Florence Molinié2, Anne-Sophie Woronoff3, Nadine Bossard4, Faiza Bessaoud5, Emilie Marrer6, Pascale Grosclaude7, Anne-Valérie Guizard8, Patricia Delafosse9, Simona Bara10, Michel Velten11, Bénédicte Lapôtre-Ledoux12, Karine Ligier13, Nathalie Léone14, Patrick Arveux15, Zoé Uhry16. 1. Registre des tumeurs de l'Hérault, Montpellier, France. Electronic address: registre-tumeur@wanadoo.fr. 2. Registre des cancers de Loire-Atlantique-Vendée, Nantes, France. 3. Registre des tumeurs du Doubs et du Territoire de Belfort, Besançon, France. 4. Service de Biostatistiques, Hospices civils de Lyon, Lyon, France. 5. Registre des tumeurs de l'Hérault, Montpellier, France. 6. Registre des cancers du Haut-Rhin, Mulhouse, France. 7. Registre des cancers du Tarn, Albi, France. 8. Registre des tumeurs du Calvados, Caen, France. 9. Registre des cancers de l'Isère, Grenoble, France. 10. Registre des cancers de la Manche, Cherbourg, France. 11. Registre des cancers du Bas- Rhin, Strasbourg, France. 12. Registre des cancers de la Somme, Amiens, France. 13. Registre des cancers de Lille et de sa zone de proximité, Lille, France. 14. Registre des cancers du Limousin, Limoges, France. 15. Registre des tumeurs gynécologique et du sein de Côte d'Or, Dijon, France. 16. Institut de Veille Sanitaire, Service de biostatistiques des Hospices civils de Lyon, Lyon, France; Service de Biostatistiques, Hospices civils de Lyon, Lyon, France.
Abstract
OBJECTIVE: The aim of this epidemiological study was to describe the incidence, mortality and survival of ovarian cancer (OC) in France, according to age, period of diagnosis, and histological type. METHODS: Incidence and mortality were estimated from 1980 to 2012 based on data in French cancer registries and from the Centre for Epidemiology of Causes of Death (CépiDc-Inserm) up to 2009. Net survival was estimated from registry data using the Pohar-Perme method, on cases diagnosed between 1989 and 2010, with date of last follow-up set at 30 June 2013. RESULTS: In 2012, 4615 cases of OC were diagnosed in France, and 3140 women died from OC. World population age-standardized incidence and mortality rates declined by respectively 0.6% and 1.2% per year between 1980 and 2012. Net survival at 5years increased slightly, from 40% for the period 1989-1993 to 45% for the period 2005-2010. Net survival varied considerably according to histological type. Germ cell tumors had better net survival at 10years (81%) compared to epithelial tumors (32%), sex cord-stromal tumors (40%) and tumors without biopsy (8%). CONCLUSIONS: Our study shows a decline in incidence and mortality rates from ovarian cancer in France between 1980 and 2012, but net survival remains poor overall, and improved only slightly over the whole study period.
OBJECTIVE: The aim of this epidemiological study was to describe the incidence, mortality and survival of ovarian cancer (OC) in France, according to age, period of diagnosis, and histological type. METHODS: Incidence and mortality were estimated from 1980 to 2012 based on data in French cancer registries and from the Centre for Epidemiology of Causes of Death (CépiDc-Inserm) up to 2009. Net survival was estimated from registry data using the Pohar-Perme method, on cases diagnosed between 1989 and 2010, with date of last follow-up set at 30 June 2013. RESULTS: In 2012, 4615 cases of OC were diagnosed in France, and 3140 women died from OC. World population age-standardized incidence and mortality rates declined by respectively 0.6% and 1.2% per year between 1980 and 2012. Net survival at 5years increased slightly, from 40% for the period 1989-1993 to 45% for the period 2005-2010. Net survival varied considerably according to histological type. Germ cell tumors had better net survival at 10years (81%) compared to epithelial tumors (32%), sex cord-stromal tumors (40%) and tumors without biopsy (8%). CONCLUSIONS: Our study shows a decline in incidence and mortality rates from ovarian cancer in France between 1980 and 2012, but net survival remains poor overall, and improved only slightly over the whole study period.
Authors: Swantje Piszczan; Dawit Desalegn; Hezkiel Petros; Mengistu Gurmu; Eric Sven Kroeber; Adamu Addissie; Rafael Mikolajczyk; Rahel G Ghebre; Assefa Mathewos; Christoph Thomssen; Ahmedin Jemal; Eva Johanna Kantelhardt Journal: Oncologist Date: 2019-04-25
Authors: Alexandra Couttenier; Olivia Lacroix; Evelien Vaes; Chris R Cardwell; Harlinde De Schutter; Annie Robert Journal: PLoS One Date: 2017-12-19 Impact factor: 3.240
Authors: Juan Fernando Sánchez Vega; Magdali Del Rocío Murillo Bacilio; Adrián Santiago Vintimilla Condoy; Araceli Miroslava Palta González; José Alfredo Crespo Astudillo; Franklin Geovany Mora-Bravo Journal: BMC Cancer Date: 2018-05-24 Impact factor: 4.430